GuidelineThe Journal of urology2008
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
Guideline in The Journal of urology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03103724 (A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.BJU international · 2016Pooled it
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Guideline
- Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.Nutrients · 2023Trial
- Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.Nutrients · 2021Trial
- Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial.JAMA oncology · 2021Trial
- Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.Integrative cancer therapies · 2018Trial
- A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.The Prostate · 2015Trial
- Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.Clinical & experimental metastasis · 2015Trial
- A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.Prostate cancer and prostatic diseases · 2013Trial
- DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.Cancer immunology, immunotherapy : CII · 2012Trial
- A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.Cancer immunology, immunotherapy : CII · 2010Trial
- Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.ESMO real world data and digital oncology · 2026Article
- Article
- Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy.BJU international · 2026Article
- Understanding the Impact of Salvage Radiation on the Long-Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.Cancer medicine · 2025Article
- Clinical factors predicting the outcome of salvage radiotherapy for patients with biochemical recurrence after radical prostatectomy.International journal of clinical oncology · 2024Article
- Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.JAMA network open · 2024Article
- Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.Prostate international · 2024Article
- Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.Cancer chemotherapy and pharmacology · 2024Article
- Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer.Prostate international · 2023Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
purposeProstate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting. MATERIALS AND
methodsIn September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use.
resultsThe Prostate Specific Antigen Working Group defined criteria regarding prostate specific antigen doubling time including the calculation of prostate specific antigen doubling time, evidence to support prostate specific antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostate specific antigen doubling time as a stratification factor in clinical trials.
conclusionsWe propose that investigators calculate prostate specific antigen doubling time before enrolling patients in clinical studies and calculate it as an additional measurement of therapeutic activity. We believe we have developed practical guidelines for the calculation of prostate specific antigen doubling time and its use as a measurement of prognosis and outcome. Furthermore, the use of common standards for prostate specific antigen doubling time in clinical trials is important as we determine which treatments should progress to randomized trials in which "hard" end points such as survival will be used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.